EBGLYSS™ (lebrikizumab-lbkz), a targeted IL-13 inhibitor from Eli Lilly and Company, has received FDA approval for the treatment of adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis (eczema)...
The newly discovered CARD14-MYC signaling pathway may play a crucial role in skin barrier function, new research suggests. Researchers suggest that CARD14 regulates skin barrier function through two mechanisms: stimulating NFκB to establish an antimicrobial barrier...
The DEF Essential Resource Meeting 2024 (DERM2024) NP/PA CME Conference wrapped up Sunday in Las Vegas, bringing to a close 5 days of comprehensive education for health care professionals in dermatology. Lectures covered career development and planning, skin cancer,...
Short-term use of JAK inhibitors for the treatment of dermatologic conditions does not appear to increase an individual’s risk of major adverse cardiovascular events (MACE) and venous thromboembolism (VTE), new research suggests. Findings come from a systematic review...
By Joe Gorelick, MSN, FNP-C Abrocitinib (Cibinqo, Pfizer) effectively and safely manages itch in prurigo nodularis (PN) and chronic pruritus (CP) of unknown origin, new data suggest. Researchers assessed the effect of treatment on 20 patients (10 with PN and 10 with...
“Forever chemicals” have been in the news, and maybe they’ve been in your clinic. From skincare and makeup products to occupational gear and more, patients are exposed to PFAS, and there could be effects on their skin. In this episode of the...
